Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

Stanway, Susannah J and Purohit, Atul and Woo, L W Lawrence and Sufi, Saulat and Vigushin, David and Ward, Rebecca and Wilson, Richard H and Stanczyk, Frank Z and Dobbs, Nicola and Kulinskaya, Elena and Elliott, Moira and Potter, Barry V L and Reed, Michael J and Coombes, R Charles (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clinical Cancer Research, 12 (5). pp. 1585-92. ISSN 1078-0432 (https://doi.org/10.1158/1078-0432.CCR-05-1996)

Abstract

Inhibition of steroid sulfatase (STS), the enzyme responsible for the hydrolysis of steroid sulfates, represents a potential novel treatment for postmenopausal women with hormone-dependent breast cancer. Estrone and DHEA are formed by this sulfatase pathway and can be converted to steroids (estradiol and androstenediol, respectively), which have potent estrogenic properties.

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Item metadata

  Item type:	Article
  ID code:	32631
  Dates:	Date Event 2006 Published
  Subjects:	Medicine > Therapeutics. Pharmacology Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer)
  Department:	Strathclyde Business School > Accounting and Finance Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
  Depositing user:	Pure Administrator
  Date deposited:	19 Aug 2011 11:00
  Last modified:	08 Apr 2024 19:19
  URI:	https://strathprints.strath.ac.uk/id/eprint/32631